
-
Ocular Therapeutix NasdaqGM:OCUL Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Location: 15 Crosby Drive, Bedford, MA, 01730, United States | Website: https://www.ocutx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.023B
Cash
349.7M
Avg Qtr Burn
-36.37M
Short % of Float
11.29%
Insider Ownership
3.49%
Institutional Own.
87.00%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DEXTENZA® (dexamethasone ophthalmic insert) Details Inflammation and pain following ophthalmic surgery | Approved Quarterly sales | |
DEXTENZA® (dexamethasone ophthalmic insert) Details Eye disease , Allergic conjunctivitis | Approved Quarterly sales | |
ReSure® Sealant Details Intraoperative management of clear corneal incision | Approved Quarterly sales | |
AXPAXLI (OTX-TKI) (axitinib intravitreal implant) Details Wet age-related macular degeneration | Phase 3 Data readout | |
OTX-CSI (cyclosporine intracanalicular insert) Details Dry eye disease | Phase 2 Data readout | |
OTX-DED (dexamethasone intracanalicular insert) Details Dry eye disease | Phase 2 Data readout | |
PAXTRAVA™ (OTX-TIC) (travoprost implant) Details Ocular hypertension, Primary open angle glaucoma | Phase 2 Update | |
AXPAXLI (OTX-TKI) (axitinib intravitreal implant) Details Eye disease , Diabetic retinopathy | Phase 1 Update |